Skip to content

Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial

Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01279031
Enrollment
25
Registered
2011-01-19
Start date
2011-10-31
Completion date
2012-01-31
Last updated
2012-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Astigmatism, Cataracts

Brief summary

The purpose of this study is to look at the outcomes of your vision after your cataract surgery based on two different types of equipment that will be used during your surgery.

Interventions

DEVICEAbbott WHITESTAR Signature System with Ellips Transversal Ultrasound

Comparison of vision after cataract surgery based on two different types of equipment.

DEVICEAlcon Infiniti wiht the OZIL Torsional Handpiece

Comparision of vision after cataract surgery based on two different types of equipment.

Sponsors

Innovative Medical
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients at least 21 scheduled to undergo bilateral phacoemulsification with implantation of multifocal IOLs. * Both eyes must have similar degrees of cataract and astigmatism (topographic cylinder difference of \<2.00D as well as similar globe axial length as measured by the IOL Master of \<0.5mm). * Visual potential of UCVA 20/25/ or better. * Clear intraocular media other than cataract.

Exclusion criteria

* Clinically relevant differences between eyes in ocular disease or pathology. * Presence of glaucoma, macular disease, or foveal disease to an asymmetrical degree. * Asymmetrical use of ocular medications.

Design outcomes

Primary

MeasureTime frame
Visual acuity1 year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026